Epidemiological burden of meningococcal disease in Latin America: A systematic literature review

Presa, Jessica; Abalos, Maria Gabriela; Almeida, Rodrigo Sini de; Cané, Alejandro

doi:10.1016/j.ijid.2019.05.006

Cited by 24 publications

(25 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent emergence and spread of the highly-virulent MenW:cc11 strain from Latin America to Europe and beyond, in particular, has led to rapid implementation of the MenACWY conjugate vaccine for teenagers and young adults, and, in some countries, toddlers and young children. 163 The recent licensure of two new protein-based MenB vaccines with broad coverage has provided a major boost for the fight against meningococcal disease in high-income countries where this serogroup is the main cause of IMD. In September 2015, the UK became the first country to implement 4CMenB into its national infant immunization programme and, three years on, large reductions have been observed in vaccine-eligible cohorts.…”

Section: Discussionmentioning

confidence: 99%

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

Parikh

Campbell

Bettinger

et al. 2020

Journal of Infection

169

155

View full text Add to dashboard Cite

Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associated with high case fatality rates and serious lifelong complications among survivors. Twelve serogroups are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningococcal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographically and over time. For the first time, effective vaccines against all these serogroups are available or nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of the world through a combination of successful meningococcal immunisation programmes and secular trends. The introduction of meningococcal C conjugate vaccines in the early 20 0 0s was associated with rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vaccine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, other serogroups have become more important causes of IMD. In particular, the emergence of a hypervirulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the recent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection against the most common group responsible for childhood IMD across Europe and Australia. This review describes global IMD epidemiology across each continent and trends over time, the serogroups responsible for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this devastating disease.

show abstract

Section: Discussionmentioning

confidence: 99%

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

Parikh

Campbell

Bettinger

et al. 2020

Journal of Infection

169

155

View full text Add to dashboard Cite

show abstract

“…Most of the cases reported are sporadic, with seasonal variations and periodic outbreaks occurring in several cities. 6 During the last 50 years, several meningococcal vaccination programmes were implemented in Brazil, providing important lessons. In the early 1970s, an epidemic of serogroup A disease, with incidence rates as high as 179 cases/100,000 population in determined regions provided the first major experience in the world with a large-scale vaccination of a polysaccharide A and C vaccine, resulting in the successful control of the epidemic one year after its implementation.…”

Section: Introductionmentioning

confidence: 99%

A critical analysis of serogroup B meningococcal disease burden in Brazil (2001–2015): implications for public health decisions

Chicuto

Moraes

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The recent licensure of two different serogroup B recombinant protein meningococcal vaccines in Brazil emphasizes the importance of a better knowledge of the real burden of serogroup B meningococcal (MenB) disease to establish evidence-based vaccination policies. We performed an observational, descriptive study, from 2001 to 2015, analyzing the incidence and case fatality rates (CFR) of MenB disease in Brazil, according to age group and region. In the absence of any vaccine use targeting MenB disease, a significant decline of 90% in the overall incidence rates of MenB disease was observed (from 0.55 cases/100,000 habitants in 2001 to 0.05 in 2015), with declines found in all age groups during the study period. The highest incidence rates were consistently observed in infants and children 1-4 year of age, whereas adults ≥ 60 years experienced the highest CFR (33.9%). The proportion of cases with serogroup identified increased from 37.1% in 2001 to 51.5% in 2015. Despite an improvement in recent years, the quality of diagnosis is highly heterogeneous in the diverse regions, presenting important deficiencies that still prevent the possibility of a robust and reliable analysis of the burden of the meningococcal disease in Brazil. Based on the findings of this study and taking in account the unlikely indirect effect associated with the use of the new recombinant serogroup B protein vaccines, infants < 1 year is the age group to be prioritized when considering the implementation of routine immunization programmes with MenB vaccines.

show abstract

“…In Tunisia, the serogroup Y represents 4.7 % (n=59) [13]. During the period 2005-2016, in Mexico, serogroup Y represents 23.53 % [28]. In one region of Brazil in 2014, 8.5% cases are of serogroup Y [28].…”

Section: Discussionmentioning

confidence: 99%

“…During the period 2005-2016, in Mexico, serogroup Y represents 23.53 % [28]. In one region of Brazil in 2014, 8.5% cases are of serogroup Y [28]. In Japan, this serogroup was the most dominant with a percentage of 42 % at the end of 2014 [29].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Mouss

Razki

Hong

et al. 2020

Access Microbiology

View full text Add to dashboard Cite

Surveillance of invasive meningococcal diseases (IMD) must be carried out regularly and continuously in order to detect the emergence of strains of reduced susceptibility to antibiotics for therapeutic and prophylactic use and the appearance of new invasive clones. Molecular-typing approaches allow reliable traceability and powerful epidemiological analysis. This is an epidemiological study of Neisseria meningitidis causing meningitis in Casablanca, Morocco. The grouping was confirmed by PCR mainly on the isolates from cerebrospinal fluid (CSF). A total of 245 confirmed isolates of N .meningitidis were obtained between 2010 and 2019 of which 93 % are of group B. Overall, 24 % of all the isolates have a reduced susceptibility to penicillin G, but no resistance to penicillin G has been reported. All the isolated strains are susceptible to third-generation cephalosporins (3GCs). Genotyping by multilocus sequence typing (MLST) of a selection of 18 strains showed that the majority of isolates belong to the invasive clonal complex CC 32(9/18) followed by the CC 41/44(3/18).

show abstract

Epidemiological burden of meningococcal disease in Latin America: A systematic literature review

Cited by 24 publications

References 54 publications

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

A critical analysis of serogroup B meningococcal disease burden in Brazil (2001–2015): implications for public health decisions

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Contact Info

Product

Resources

About